153 related articles for article (PubMed ID: 35202852)
1. Recent developments on 1,8-Naphthalimide moiety as potential target for anticancer agents.
Tandon R; Luxami V; Tandon N; Paul K
Bioorg Chem; 2022 Apr; 121():105677. PubMed ID: 35202852
[TBL] [Abstract][Full Text] [Related]
2. An Outlook of the Structure Activity Relationship (SAR) of Naphthalimide Derivatives as Anticancer Agents.
Bhat AA
Anticancer Agents Med Chem; 2024; 24(2):96-116. PubMed ID: 37974443
[TBL] [Abstract][Full Text] [Related]
3. 1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.
Tandon R; Luxami V; Kaur H; Tandon N; Paul K
Chem Rec; 2017 Oct; 17(10):956-993. PubMed ID: 28375569
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
Tomczyk MD; Byczek-Wyrostek A; Strama K; Wawszków M; Kasprzycki P; Walczak KZ
Med Chem; 2019; 15(5):550-560. PubMed ID: 30207241
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, electrochemistry, DNA binding and in vitro cytotoxic activity of tripodal ferrocenyl bis-naphthalimide derivatives.
Fan YR; Wang BJ; Jia DG; Yang XB; Huang Y
J Inorg Biochem; 2021 Jun; 219():111425. PubMed ID: 33831713
[TBL] [Abstract][Full Text] [Related]
6. Naphthalimide derivatives with therapeutic characteristics: a patent review.
Kamal A; Bolla NR; Srikanth PS; Srivastava AK
Expert Opin Ther Pat; 2013 Mar; 23(3):299-317. PubMed ID: 23369185
[TBL] [Abstract][Full Text] [Related]
7. l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.
Tomczyk MD; Walczak KZ
Eur J Med Chem; 2018 Nov; 159():393-422. PubMed ID: 30312931
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of naphthalimide-carborane and metallacarborane conjugates: Anticancer activity, DNA binding ability.
Nekvinda J; Różycka D; Rykowski S; Wyszko E; Fedoruk-Wyszomirska A; Gurda D; Orlicka-Płocka M; Giel-Pietraszuk M; Kiliszek A; Rypniewski W; Bachorz R; Wojcieszak J; Grüner B; Olejniczak AB
Bioorg Chem; 2020 Jan; 94():103432. PubMed ID: 31776032
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, DNA Binding, and Anticancer Properties of Bis-Naphthalimide Derivatives with Lysine-Modified Polyamine Linkers.
Huang Y; Wu CX; Song Y; Huang M; Tian DN; Yang XB; Fan YR
Molecules; 2018 Jan; 23(2):. PubMed ID: 29382135
[TBL] [Abstract][Full Text] [Related]
10. Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor.
Zhang HY; Han LL; Wu HY; Xu XX; Yu MB; Chen GY; Qi XL
Technol Cancer Res Treat; 2024; 23():15330338231225861. PubMed ID: 38225189
[TBL] [Abstract][Full Text] [Related]
11. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.
Xie L; Cui J; Qian X; Xu Y; Liu J; Xu R
Bioorg Med Chem; 2011 Jan; 19(2):961-7. PubMed ID: 21208805
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents.
Banerjee S; Veale EB; Phelan CM; Murphy SA; Tocci GM; Gillespie LJ; Frimannsson DO; Kelly JM; Gunnlaugsson T
Chem Soc Rev; 2013 Feb; 42(4):1601-18. PubMed ID: 23325367
[TBL] [Abstract][Full Text] [Related]
13. Lysosomes-targeting imaging and anticancer properties of novel bis-naphthalimide derivatives.
Rong RX; Wang SS; Liu X; Li RF; Wang KR; Cao ZR; Li XL
Bioorg Med Chem Lett; 2018 Feb; 28(4):742-747. PubMed ID: 29342415
[TBL] [Abstract][Full Text] [Related]
14. Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides.
Li F; Cui J; Guo L; Qian X; Ren W; Wang K; Liu F
Bioorg Med Chem; 2007 Aug; 15(15):5114-21. PubMed ID: 17532640
[TBL] [Abstract][Full Text] [Related]
15. Overview of naphthalimide analogs as anticancer agents.
Lv M; Xu H
Curr Med Chem; 2009; 16(36):4797-813. PubMed ID: 19929786
[TBL] [Abstract][Full Text] [Related]
16. Effect of intercalator substituent and nucleotide sequence on the stability of DNA- and RNA-naphthalimide complexes.
Johnson CA; Hudson GA; Hardebeck LK; Jolley EA; Ren Y; Lewis M; Znosko BM
Bioorg Med Chem; 2015 Jul; 23(13):3586-91. PubMed ID: 25960324
[TBL] [Abstract][Full Text] [Related]
17. Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1-c][1,4]benzodiazepine-naphthalimide conjugates linked through piperazine side-armed alkane spacers.
Kamal A; Ramu R; Tekumalla V; Khanna GB; Barkume MS; Juvekar AS; Zingde SM
Bioorg Med Chem; 2008 Aug; 16(15):7218-24. PubMed ID: 18656370
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of naphthalimide derivatives with potential anticancer activity, their comparative ds- and G-quadruplex-DNA binding studies and related biological activities.
Yildiz U; Kandemir I; Cömert F; Akkoç S; Coban B
Mol Biol Rep; 2020 Mar; 47(3):1563-1572. PubMed ID: 32095985
[TBL] [Abstract][Full Text] [Related]
19. Novel naphthalimide-benzoic acid conjugates as potential apoptosis-inducing agents: design, synthesis, and biological activity.
Wu A; Mei P; Xu Y; Qian X
Chem Biol Drug Des; 2011 Dec; 78(6):941-7. PubMed ID: 21958160
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new amonafide analogues via coupling reaction and their cytotoxic evaluation and DNA-binding studies.
Xie L; Xu Y; Wang F; Liu J; Qian X; Cui J
Bioorg Med Chem; 2009 Jan; 17(2):804-10. PubMed ID: 19070496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
